Neurosensorial Disorder and Pain in Oral Cavity and Oropharynx Cancer Traited Patients (OCAPA)
NCT ID: NCT04673981
Last Updated: 2025-09-02
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
RECRUITING
NA
120 participants
INTERVENTIONAL
2020-07-31
2028-07-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
The objective of the study is to map and qualitatively evaluate neurosensory disorders in patients treated for cancers of the oral cavity and oropharynx.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Study to Evaluate the Interest of Qutenza in Patients With Head and Neck Cancer in Remission and With Sequelae Neuropathic Pain.
NCT04704453
Nerve Changes in Patients Who Are Undergoing Chemotherapy or Biological Therapy for Cancer
NCT00281853
Chronic Neuropathy Following Chemotherapy
NCT02654691
Understanding Risk Factors and Determinants for Neuropathic Pain
NCT02402361
The Role of TRP Channels in CIPN
NCT04415892
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
PART 1: Collection of Data and Consent
* Patient Data:
* Date of visit and inclusion in the study
* Patient initials
* Age
* Gender (male or female)
* The weight
* The size
* Verification of inclusion and non-inclusion criteria:
* General patient history:
* Patient history
* Ongoing Treatments
* Professional activity
* Tumor:
* Features
* Location
* TNM
* Histological type
* Search for risk factors for peripheral neuropathy
* Check for symptoms of peripheral neuropathy.
PART 2: Collecting Treatment Data
* Operating data:
* Operation date
* Type of surgery
* Duration of surgery
* Severed sensory nerves
* Perioperative complications
* On the way out:
* Adjuvant treatment including radiotherapy and/or chemotherapy.
* Exit analgesic treatment
* EN (Numerical Scale)
PART 3: Collection of data related to neurosensory disorders and pain
* Analgesics consumed
* Questionnaire DN4 for each operated area separated according to the curage, lumpectomy and reconstruction if they take place.
* If DN4 positive, completion of the QCD and QEDN questionnaires.
* Clinical examination for sensory disturbances reported on a chart.
* Generic quality of life questionnaire adapted to cancer pathology EORTC QLQC30 and its specific Head and Neck35 add-on module adapted to head and neck cancers.
* Thermotest and hot water, cold water (for the oral cavity)
* HADS Questionnaire
* Catastrophe Questionnaire
* Quantitative sensory testing (QST) for neuropathic patients :
Mechanical neurosensory disorders will be tested with the Von frey filament and the brush.
* Hypoesthesia or mechanical anaesthesia will be sought with the Von Frey filament and the brush.
* Mechanical hypersensitivity, a painful sensation exacerbated by a sharp, non-traumatic object, will be sought with a large calibre Von Frey filament.
* Static Allodynia, felt painful on contact, will be sought at Von Frey's filament.
* Dynamic Allodynia, felt painful when rubbed, will be sought with a wide brush (8 mm) over a distance of several centimetres.
Thermal neurosensory disorders will be sought for the skin with the Thermotest and at the level of the oral cavity with the application of standardised test tubes containing water at 4°C stored in the fridge or hot water at 63°C (the protocol consists of heating water at 4°C in the microwave for 30 seconds to obtain the temperature of 63°C); these examinations will allow the evaluation of thermal allodynia and hypoesthesia.
The examination will cover the entire face, the oral cavity, the cervical region and the area where the reconstruction flaps are taken. The pathological areas identified will be delimited on diagrams previously made with a coding according to the sensations collected.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NA
SINGLE_GROUP
DIAGNOSTIC
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
patient treated for a oral cavity and oropharynx cancer
questionnaire and tests to evaluate neuropathic pain
diagnostic tes for neuropathic pain
Thermotest and hot water, cold water (for the oral cavity), Von frey filament and the brush
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
diagnostic tes for neuropathic pain
Thermotest and hot water, cold water (for the oral cavity), Von frey filament and the brush
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Women or men upper 18 years old)
* Patient with full consent, aware and signed
* Patient cover by the French social security system
Exclusion Criteria
* Pregnant women or nursing
* Patients who can't comply with the protocol
* Participation refusal
* Inable full age patient or under judicial protection
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
University Hospital, Clermont-Ferrand
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Nathalie PHAM DANG
Role: PRINCIPAL_INVESTIGATOR
University Hospital, Clermont-Ferrand
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
CHU de Clermont-Ferrand
Clermont-Ferrand, , France
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
2020-A00476-33
Identifier Type: OTHER
Identifier Source: secondary_id
RBHP 2020 PHAM DANG
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.